# Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)

> **NCT07204977** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 30 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis
- Motor Neuron Disease

## Interventions

- **DRUG:** Acamprosate calcium

## Key facts

- **NCT ID:** NCT07204977
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-02-02
- **Primary completion:** 2027-09-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07204977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07204977, "Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07204977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*